Cargando…

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial

BACKGROUND: Improved heart failure (HF) risk stratification after a recent acute coronary syndrome may identify those who can benefit from therapies that reduce HF risk. We aimed to identify clinical and biomarker predictors for expanded HF outcomes in patients with type 2 diabetes mellitus after re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Abhinav, Vaduganathan, Muthiah, Ferreira, João Pedro, Liu, Yuyin, Bakris, George L., Cannon, Christopher P., White, William B., Zannad, Faiez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988143/ https://www.ncbi.nlm.nih.gov/pubmed/31902327 http://dx.doi.org/10.1161/JAHA.119.012797

Ejemplares similares

Early and Chronic Dipeptidyl‐Peptidase‐IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial
por: Sharma, Abhinav, et al.
Publicado: (2018)

Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Average Clinician‐Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial
por: White, William B., et al.
Publicado: (2018)

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial
por: Heller, Simon R., et al.
Publicado: (2017)

Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

High‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial
por: Hwang, You‐Cheol, et al.
Publicado: (2017)

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
por: Stienen, Susan, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
por: Mehra, Mandeep R, et al.
Publicado: (2019)

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
por: Zannad, Faiez, et al.
Publicado: (2019)

Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
por: Sharma, Abhinav, et al.
Publicado: (2022)

The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?
por: Bhatt, Ankeet S., et al.
Publicado: (2020)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
por: Sharma, Abhinav, et al.
Publicado: (2023)

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
por: Neves, João Sérgio, et al.
Publicado: (2022)

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk
por: Ferreira, João Pedro, et al.
Publicado: (2021)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
por: Ostrominski, John W., et al.
Publicado: (2022)

Blood pressure reduction and anti‐hypertensive treatment choice: A post‐hoc analysis of the SPRINT trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Introduction
por: Zannad, Faiez
Publicado: (2019)

Un chercheur à succès est un chercheur qui a échoué et a recommencé
por: Zannad, Faiez
Publicado: (2022)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Closer to FREEDOM From Uncertainty
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
por: Rossignol, Patrick, et al.
Publicado: (2020)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Manual Thrombectomy in Myocardial Infarction: Aspiring for Better
por: Vaduganathan, Muthiah, et al.
Publicado: (2015)

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sg6ssm1m0lb543iccuu67h8vor